A Phase I/II, Open Label, Multicenter, Single-Arm, Safety and Efficacy Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers (MTC-DOX) Administered by Intrahepatic Delivery (Via Hepatic Artery Catheterization) for the Treatment of Patients With Unresectable Hepatocellular Carcinoma
Latest Information Update: 11 Oct 2005
At a glance
- Drugs MTC DOX (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 11 Oct 2005 New trial record.